Wednesday, July 8, 2026

biotech · Respiratory Distress Syndrome · Cardiogenic Shock · WINT

WINDTREE THERAPEUTICS INC

Windtree Therapeutics is a biotech organization headquartered in Warrington, USA. It trades on NYSE under ticker WINT. Primary therapeutic focus areas include Respiratory Distress Syndrome, Cardiogenic Shock, Respiratory

2600 Kelly Rd., Suite 100, Warrington, PA 18976, US HQ
1992 Founded
17 Employees
Public company Type
WINT · NYSE Ticker
Company details
Status
Public
HQ
2600 Kelly Rd., Suite 100, Warrington, PA 18976, US
Founded
1992
Employees
17
Programs
15
Drugs
9
Patents
4
Clinical program

Lucinactant for inhalation

Phase 2 · other · Respiratory Distress Syndrome

Lucinactant for inhalation for Respiratory Distress Syndrome is a Phase 2 program (other) at WINDTREE THERAPEUTICS INC /DE/ with 2 ClinicalTrials.gov record(s).

Internal code 03-CL-1401

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
WINDTREE THERAPEUTICS INC /DE/
Phase
Phase 2
Modality
other
Indication
Respiratory Distress Syndrome
Status
terminated
Trials
2